General Information of This Antibody-drug Conjugate (ID: DRG0QMVMW)
ADC Name
Dara-DVA-I030
Synonyms
Dara-DVA-I030
   Click to Show/Hide
Drug Status
Investigative
Drug-to-Antibody Ratio
~4
Structure
Antibody Name
Daratumumab
 Antibody Info 
Antigen Name
ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 (CD38)
 Antigen Info 
Payload Name
I030
 Payload Info 
Payload Target
IKZF1/3
 Target Info 
Linker Name
MC-DVA-PABC
 Linker Info 
Conjugate Type
Random conjugation through reduced inter-chain cysteines
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 3 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Inhibitory Concentration (IC50) 
0.142
nM
CVCL_1600
Multiple myeloma
Half Maximal Inhibitory Concentration (IC50) 
0.385
nM
CVCL_8792
Multiple myeloma
Half Maximal Inhibitory Concentration (IC50) 
> 10
nM
CVCL_0140
Normal
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 3 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
0.142 nM
In Vitro Model Plasma cell myeloma NCI-H929 cells CVCL_1600
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
0.385 nM
In Vitro Model Plasma cell myeloma, Multiple myeloma MM.1S cells CVCL_8792
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) > 10 nM
In Vitro Model Normal PBMC cells CVCL_0140
References
Ref 1 Rational engineering of degradation tail-driven CELMoD-antibody conjugates for precision malignancy therapy